Suzhou MedicalSystem Technology 관리

관리 기준 확인 0/4

Suzhou MedicalSystem Technology CEO는 Weng Kang, Jan2023 에 임명되었습니다 의 임기는 1.83 년입니다. 는 CN¥ 235.68M 가치에 해당하는 회사 주식의 6.88% 직접 소유합니다. 235.68M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 1.8 년입니다.

주요 정보

Weng Kang

최고 경영자

CN¥2.6m

총 보상

CEO 급여 비율	n/a
CEO 임기	1.8yrs
CEO 소유권	6.9%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) Held Back By Insufficient Growth Even After Shares Climb 29%

Oct 01

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

Jun 26

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Mar 08

CEO

Weng Kang (56 yo)

1.8yrs

테뉴어

CN¥2,600,000

보상

Mr. Weng Kang serves as Vice Chairman at Suzhou MedicalSystem Technology Co., Ltd., since January 9, 2023 and serves as its General Manager since January 10, 2023. He serves as General Manager and Executiv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Weng Kang	Vice Chairman & GM	1.8yrs	CN¥2.60m	6.88% CN¥ 235.7m
Zhuzhu Zhou	Joint GM & Director	1.8yrs	CN¥2.59m	데이터 없음
Jianghua Wang	Deputy GM & Director	1.8yrs	CN¥1.44m	0.0077% CN¥ 262.8k
Di Wu	Deputy General Manager	1.8yrs	CN¥2.21m	0.017% CN¥ 576.4k
Jie Chen	Deputy General Manager	less than a year	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 603990 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Weng Kang	Vice Chairman & GM	12.1yrs	CN¥2.60m	6.88% CN¥ 235.7m
Zhuzhu Zhou	Joint GM & Director	1.8yrs	CN¥2.59m	데이터 없음
Jianghua Wang	Deputy GM & Director	1.8yrs	CN¥1.44m	0.0077% CN¥ 262.8k
Biao Li	Chairman of the Supervisory Board	2.4yrs	데이터 없음	0.13% CN¥ 4.3m
Ning Chen	Chairman	2.5yrs	데이터 없음	데이터 없음
Dong Li	Independent Director	1.8yrs	CN¥147.20k	데이터 없음
Jun Jiang	Supervisor	1.8yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 이사회: 603990 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Suzhou MedicalSystem Technology 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Suzhou MedicalSystem Technology Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.30 loss per share (vs CN¥0.075 loss in 3Q 2023)

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) Held Back By Insufficient Growth Even After Shares Climb 29%

Suzhou MedicalSystem Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.26 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2024 Results on Aug 10, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.038 loss in 1Q 2023)

Suzhou MedicalSystem Technology Co., Ltd., Annual General Meeting, May 20, 2024

Suzhou MedicalSystem Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) announces an Equity Buyback for CNY 30 million worth of its shares.

Suzhou MedicalSystem Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.075 loss per share (vs CN¥0.008 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.041 profit in 2Q 2022)

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 profit in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.011 loss per share (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.054 (vs CN¥0.046 in 2Q 2021)

Investor sentiment deteriorated over the past week

Mianyang Haoxiang Holdings Co., Ltd agreed to acquire an unknown minority stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Weng Kang, Yan Huanghong, Wang Jianhua and Fu Hong for approximately CNY 340 million.

Suzhou MedicalSystem Technology Co., Ltd. announced that it expects to receive CNY 238.92928 million in funding from Mianyang Haoxiang Holdings Co., Ltd

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 24% undervalued

Now 22% undervalued

Now 21% undervalued

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.06 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.12 loss in 1Q 2020)

New 90-day low: CN¥29.95

New 90-day low: CN¥30.70

New 90-day low: CN¥31.00

New 90-day low: CN¥37.65

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an agreement to acquire remaining 49% stake in Haikou Mary Hospital Co., Ltd.

Third quarter earnings released

Suzhou MedicalSystem Technology Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥41.30

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an equity acquisition intention agreement to acquire 51% stake in Heilongjiang Tianyuan Obstetrics and Gynecology Hospital Co., Ltd. from Tibet Daming Investment Management Co., Ltd. and Xue Weiwei for approximately CNY 170 million.

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed a letter of intent to acquire 51% stake in a Hospital located in Heilongjiang for approximately CNY 170 million.

Earnings released

Zhongruo (Suzhou) Asset Management Co., Ltd. completed the acquisition of 5.34% stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Hangzhou Anshi Investment Management Partnership Enterprise (Limited Partnership).

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령